MSD’s Keytruda has been awarded full approval in the US in combination with Lilly’s Alimta and platinum chemotherapy as first-line treatment for metastatic non-squamous non-small cell lung cancer.
Read More
MSD has unveiled further data from a trial showing that a combination of Keytruda and chemotherapy significantly improved overall survival in patients with metastatic non-squamous non-small-cell lung cancer (NSCLC).
Read More
A combination of MSD’s Keytruda and chemotherapy extended overall survival when used as a first-line treatment of patients with metastatic non-squamous non-small-cell lung cancer (NSCLC).
Read More
